Equities Analysts Issue Forecasts for MNPR FY2026 Earnings

Monopar Therapeutics Inc. (NASDAQ:MNPR) – Research analysts at HC Wainwright boosted their FY2026 earnings per share estimates for shares of Monopar Therapeutics in a report released on Wednesday, January 22nd. HC Wainwright analyst S. Lee now anticipates that the company will post earnings of $0.70 per share for the year, up from their previous forecast of $0.12. HC Wainwright currently has a “Buy” rating and a $40.00 target price on the stock. The consensus estimate for Monopar Therapeutics’ current full-year earnings is ($1.65) per share. HC Wainwright also issued estimates for Monopar Therapeutics’ FY2027 earnings at $2.10 EPS and FY2028 earnings at $3.04 EPS.

Monopar Therapeutics (NASDAQ:MNPR) last issued its earnings results on Friday, November 8th. The company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.46) by $0.09.

MNPR has been the topic of several other reports. Rodman & Renshaw began coverage on Monopar Therapeutics in a report on Friday, October 11th. They set a “buy” rating and a $50.00 target price on the stock. Piper Sandler started coverage on Monopar Therapeutics in a report on Friday, January 10th. They issued an “overweight” rating and a $72.00 price objective on the stock.

Monopar Therapeutics Price Performance

Shares of Monopar Therapeutics stock opened at $41.46 on Friday. The stock has a market cap of $252.91 million, a P/E ratio of -21.05 and a beta of 1.23. The stock’s 50 day simple moving average is $24.19 and its 200-day simple moving average is $12.34. Monopar Therapeutics has a 1-year low of $1.54 and a 1-year high of $41.94.

Insider Activity at Monopar Therapeutics

In other news, CFO Karthik Radhakrishnan bought 1,550 shares of the business’s stock in a transaction on Monday, October 28th. The shares were bought at an average price of $16.25 per share, with a total value of $25,187.50. Following the completion of the transaction, the chief financial officer now directly owns 1,550 shares in the company, valued at $25,187.50. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 34.90% of the stock is currently owned by insiders.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.